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Abstract
Objectives
To report on trends of tuberculosis ascertainment among HIV patients in a rural HIV cohort
in Tanzania, and assessing the impact of a bundle of services implemented in December
2012, consisting of three components:(i)integration of HIV and tuberculosis services; (ii)
GeneXpert for tuberculosis diagnosis; and (iii)electronic data collection.
Design
Retrospective cohort study of patients enrolled in the Kilombero Ulanga Antiretroviral Co-
hort (KIULARCO), Tanzania.)
Methods
HIV patients without prior history of tuberculosis enrolled in the KIULARCO cohort between
2005 and 2013 were included.Cox proportional hazard models were used to estimate rates
and predictors of tuberculosis ascertainment
Results
Of 7114 HIV positive patients enrolled, 5123(72%) had no history of tuberculosis. Of these,
66% were female, median age was 38 years, median baseline CD4+ cell count was 243
cells/µl, and 43% hadWHO clinical stage 3 or 4. During follow-up, 421 incident tuberculosis
cases were notified with an estimated incidence of 3.6 per 100 person-years(p-y)[95% con-
fidence interval(CI)3.26-3.97]. The incidence rate varied over time and increased
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significantly from 2.96 to 43.98 cases per 100 p-y after the introduction of the bundle of ser-
vices in December 2012. Four independent predictors of tuberculosis ascertainment were
identified:poor clinical condition at baseline (Hazard Ratio (HR) 3.89, 95% CI 2.87-5.28),
WHO clinical stage 3 or 4 (HR 2.48, 95% CI 1.88-3.26), being antiretroviralnaïve (HR 2.97,
95% CI 2.25-3.94), and registration in 2013(HR 6.07, 95% CI 4.39-8.38).
Conclusion
The integration of tuberculosis and HIV services together with comprehensive electronic
data collection and use of GeneXpert increased dramatically the ascertainment of tubercu-
losis in this rural African HIV cohort.
Introduction
Tuberculosis (TB) remains the most common opportunistic infection among HIV-infected pa-
tients, in particular in sub-Saharan Africa (SSA), and can occur at any stage of HIV disease [1].
According to recent studies and reports from Tanzania, about 10% of all HIV-infected individ-
uals develop active TB[2] whereas nearly half of TB patients are co-infected with HIV[3].
Trends of TB notification in Africa have decreased over time[4–6], which has been mostly
attributed to improved screening and provision of antiretroviral therapy (ART) among
TB-HIV infected individuals [5,6]. However, TB cases per population in SSA are still highest
compared to other regions [4]. Lack of widely available point of care robust tools for TB diag-
nosis, high prevalence of HIV infection, and challenges in reporting of TB remain obstacles for
TB control in SSA[4]. Moreover, diagnosis of TB in SSA often relies on the use of microscopy,
radiological findings and clinical symptoms, and in most cases culture is not routinely per-
formed due to minimal capacity and lack of infrastructure[7,8].
In December 2012, the Chronic Disease Clinic of Ifakara (CDCI) situated within the Saint
Francis Referral Hospital (SFRH) in Ifakara, south-central Tanzania, introduced a bundle of
services to optimize the functioning of the clinic in general and the diagnosis and management
of TB-HIV cases in particular. This bundle of services consisted of three main components,
namely the integration of TB and HIV services within one single facility, the use of GeneXpert
(Cepheid, Sunnyvale CA) for TB diagnosis, and the introduction of an electronic data collec-
tion system.
Several studies have shown independent effectiveness of each of these strategies [9–22]. The
WHO recommends integrating service delivery, use of point of care diagnosis, and replacing of
paper clinic logs with electronic medical records. We hypothesized that the implementation of
this bundle of services in our rural HIV cohort in Tanzania in December 2012 may have in-
creased the rate of TB ascertainment.
Methods
Study design and setting
We conducted a retrospective cohort study using the KIULARCO cohort database between
2005 and 2013. This cohort is comprised of all patients visited at the Chronic Diseases Clinic of
Ifakara, Morogoro, southern Tanzania, who give their informed consent to participate. Details
of the KIULARCO cohort are given elsewhere[23,24].
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Participants
We included all patients enrolled in KIULARCO between 2005 and 2013. Exclusion criteria in-
cluded:(i) reported history of TB; (ii) lack of follow-up information; and (iii) referral from a TB
clinic. The KIULARCO studywasreviewed and approved by the IfakaraHealthInstitute (IHI)
institutional reviewboard and the National Institute for MedicalResearch (NIMR) of Tanzania.
Informed consent to participate in the KIULARCO cohort is sought from all patients upon reg-
istration in the Chronic Diseases Clinic of Ifakara. Regular supply of ART was introduced in
our clinic in 2005.
Variables and data source
Outcome. The outcome variable was TB recording in the KIULARCO database during the
follow-up period, defined as having one of the following recorded in the database: 1) TB diag-
nosis, 2) positive sputum smear, 3) positive GeneXpert in sputum or other extra pulmonary
sample 4) chest X-ray suggestive of TB together with at least one reported symptom of TB, or
5) having been treated with anti-tuberculosis drugs. We included both pulmonary and extra-
pulmonary TB cases. Before the introduction of the electronic medical record in December
2012, data was collected using paper-based questionnaires filled by the clinicians at each visit
and double data entered in anelectronic database by 2 data clerks. The structure of the ques-
tionnaire was entirely based on the patient record form of the Tanzanian National AIDS Con-
trol Program. Questions specifically concerning TB included screening questions (cough,
weight loss, chronic fever, fatigue, night sweats), and TB diagnosis (yes/no/diagnosed today).
Predictors of tuberculosis ascertainment. The potential explanatory variables for tuber-
culosis ascertainment assessed included sex, age, marital status, baseline CD4 counts, WHO
clinical stage, ART treatment, smoking, history of chronic illness (cancer, diabetes, hyperten-
sion), period of registration, and functional status. All variables were obtained from the KIU-
LARCO cohort database.
Definitions
Integration of TB and HIV within one facility. Before the introduction of the bundle of
services, the TB and HIV care and treatment services at Saint Francis Referral Hospital were
running in parallel and patients were referred between the two facilities. Integration of TB and
HIV services included bringing all services under one facility. After the start of the bundle of
service HIV patients are systematically screened for TB symptoms at each visit and, in turn, all
patients diagnosed with TB are screened for HIV. Clinicians specifically ask for TB symptoms
using the World Health Organization (WHO) symptom screening tool [25] and request a
chest radiography and sputum smear for bacilloscopy+/- GeneXpert analysis if symptoms of
pulmonary tuberculosis are detected. Treatments of both diseases are provided at the same in-
tegrated HIV-TB clinic, under the same roof, and by the same medical staff. All staffs at the
CDCI underwent training on screening of TB among HIV, HIV among TB, infection control
as well as procedural changes at the clinic to accommodate new system changes. In addition,
two different waiting areas and entrance to the clinic as well as two different sites for drug dis-
pensing were accommodated to avoid contact between TB and HIV patients.
Use of GeneXpert. GeneXpert was introduced in order to improve timely detection and di-
agnosis of TB among individuals with or without diagnosis of HIV. Sputum or extra-pulmonary
samples are obtained from TB suspects when feasible. Results are made available to the clinic
within two hours and treatment is started immediately in case of a positive result.
Use of electronic data collection system. Previously existing case report forms (CRF)
were optimised to include all detailed visit information, concerning medical history, physical
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examination and diagnoses using International Classification of Diseases (ICD)-10 codes, ART
toxicity, drug prescription and refill information, as well as laboratory results. An electronic
medical record system was then developed based on these new CRFs using the OpenMRS plat-
form (http://openmrs.org/) and all paper forms were fully replaced. The system, designed to
comprehensively capture all clinically relevant information and minimising missing data and
data entry mistakes, was launched in December 2012 and has been used without interruption
at the CDCI ever since.
Statistical methods
Baseline characteristics were summarized as proportions/percentages for categorical variables
and medians and interquartile ranges for continuous variables. Annual specific notification in-
cidence rates, cumulative incidence rates pre- and during 2013, and incidence rates by selected
variables were calculated using Cox proportional hazard model. Estimated number of TB
cases, person-years incidence rates and 95% confidence interval (CI) were presented. In addi-
tion, the incidence of early tuberculosis ascertainment was assessed by separately calculating
the rate of tuberculosis ascertainment in those diagnosed within a month of registration.
Cox proportional hazard models were used to determine independent predictors of tubercu-
losis ascertainment in order to assess the impact of the bundle of services introduced in Decem-
ber 2012. Hazard ratios, 95% CI, and Wald p values were calculated. Follow-up started at
enrolment and patients were censored at the earliest date of the following: first TB diagnosis,
last follow-up visit, death, withdrawal from the cohort, or December 31, 2013. We considered
events contributing to the follow up if they happen within the period of registration(eg events
only count for patients registered prior to 2013 if they happen prior to 2013). We conducted a
complete case analysis for all variables in the multivariate analysis and for variables with more
than 10% of records missing were assessed in the univariable analysis but not included in the
multivariable models. The characteristics of patients with and without missing records for such
variables were compared to assess potential systematic differences between patients with and
without missing data. The choice of confounders was made based on literature review and clin-
ical knowledgeand all predictors were selected apriori and included in the final
multivariable model.
Finally, a sensitivity analysis was done in order to estimate the impact of the bundelon early
diagnosis and diagnosis on new cases. First we estimated the rate of ascertainment on only pa-
tients diagnosed within a month of registration and second estimating rate by excluding those
diagnosed within the first month of registration. Data were extracted, processed and analysed
using SAS v9.3 (SAS Institute, North Caroline, USA) and STATA v12 (StataCorp, Texas,
USA).
Results
A total of 7114 HIV-infected patients were enrolled in the KIULARCO cohort between January
2005 and December 2013. Of these, 5123 were eligible for the study (Fig 1). At the time of en-
rolment, the median age was 38 years (Interquartile range (IQR): 30.6, 46) and median CD4
count was 243 cells/μl (IQR: 102, 477). Sixty-six percent were female, 45% were married and
92% were residents of the Kilombero district. Late presentation was common with 27% and
16% enrolling with WHO stage 3 and 4 respectively, and 63% with350 CD4 cells/μl. Six per-
cent of patients were on ART at enrolment and 84% started ART during follow-up, with 80%
reporting good adherence. Social demographic and clinical characteristics of the study popula-
tion did not differ with those of the entire cohort (Table 1).
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Fig 1. Flow diagram of the study population.
doi:10.1371/journal.pone.0123275.g001
Table 1. Summary of the baseline characteristics of study participants.
Pre 2013 Post 2013
Characteristic Study population
(N = 6622)
Eligible population
(N = 4772)
Study population
(N = 492)
Eligible population
(N = 351)
Age (years), median (IQR) 38.1 (30.6–46.1) 38.2 (30.6–46) 36.2 (29.6–45.4) 36 (29.8–45.6)
Male Gender, n (%) 2403 (36.6) 1610 (33.9) 168 (34.2) 110 (31.3)
WHO clinical stage, n (%)
Stage III/IV 2204 (52) 1357 (41.8) 265 (55.5) 180 (51.9)
CD+4 cell count, n (%)
Median (IQR)cells/ul 228 (91–449) 242 (102.7–477) 201 (66.5–418.5) 201 (67–387)
350cells/ul 1501 (65.4) 938 (62.7) 304 (69.1) 230 (71.4)
On ART during follow-up, n (%) 4970 (83.7) 4034 (84.6) 301 (61.2) 260 (74.1)
Functional status, n (%)
Working 5142 (89.3) 4214 (91.5) 416 (85.1) 313 (89.7)
Ambulatory 502 (8.7) 308 (6.7) 52 (10.6) 25 (7.2)
Bedridden 109 (2) 83 (1.8) 21 (4.3) 11 (3.1)
Alcohol use, n (%) 1603 (27.7) 1127 (27.8) 77 (15.6) 53 (15.1)
Smoking, n (%) 894 (15.4) 601 (14.8) 14 (2) 8 (2.3)
History of chronic diseases, n (%) 942 (15.7) 673 (15.9) 6 (1.2) 4 (1.1)
Percentages exclude missing values: Chronic diseases include arterial hypertension, diabetes mellitus and cancer. KIULARCO: Kilombero Ulanga
Antiretroviral Cohort; IQR: Interquartile range; WHO: World Health Organization, ART: Antiretroviral treatment
doi:10.1371/journal.pone.0123275.t001
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Tuberculosis ascertainment
In total 421 TB cases were registered in the KIULARCO cohort between 2005 and 2013. Of
these 81 had been registered in 2013, and 47 of the patients registered prior to 2013 developed
TB in 2013. Thus, 128/421 (30%) TB cases were diagnosed in 2013. GeneXpert contributed to
12% (15/128) of all TB diagnostics in 2013.
The overall person-years (p-y) of follow-up was 11,323 (11,149 p-y prior to 2013 and 175 p-
y post 2013) and the incidence rate of TB ascertainment was 3.60 per 100 p-y (95% CI: 3.26–
3.97) during the study period. The incidence rate before 2013 was 2.96 per 100 p-y (95% CI:
2.66–3.30) and 43.98 per 100 p-y (95% CI: 35.18–54.99) during 2013 (Fig 2). The incidence
rate of TB was higher among males (3.98 per 100 p-y; 95% CI: 3.38–4.67), patients aged<18
years (4.40 per 100 p-y; 95% CI: 3.31–5.83), ART naïve individuals (7.67 per 100 p-y 95%CI
6.28–9.37) and those with baseline WHO clinical stage 3 or 4 (8.30 per 100 p-y; 95% CI: 7.27–
9.46, Table 2).
During the same period,1868 TB cases were reported from Saint Francis Referral Hospital
to the National Tuberculosis and leprosy programme (NTLP). Of them, 1363 (73%) were pul-
monary TB and 505 (27%) extrapulmonary. Only 27% of pulmonary cases were confirmed
through microscopy smear. In 2013, 84% (141/167) of all TB/HIV cases reported to the NTLP
from our hospital were captured in the KIULARCO database as compared with 16% (280/
1701) prior to 2013.
Predictors of tuberculosis ascertainment
In univariate analysis, being single, WHO clinical stage 3 or 4, having a poor functional status
at baseline (being bedridden or unable to work), CD4 count350 cells/μl, ART-naivety, and
registration in 2013 versus pre-2013 were associated with an increased rate of TB recording in
the KIULARCO database.
Fig 2. Incidence rate of tuberculosis ascertainment over time, 2005–2013.
doi:10.1371/journal.pone.0123275.g002
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Four baseline independent predictors of increased risk of TB ascertainment were identified
in the multivariate analysis: registration in 2013 (HR 6.07, 95% CI: 4.39–8.38), WHO stage 3 or
4 (HR 2.48, 95% CI: 1.88–3.26), poor functional status at baseline (HR 3.89, 95% CI; 2.87–
5.28), and ART-naivety (HR 2.97, 95%CI 2.25–3.94), Table 3).
Early tuberculosis diagnosis
In total 126 TB cases were recorded in KIULARCO within a month after enrolment, 73 pre-
and 53 post-2012. Seventy-five percent (55/73) and 81% (43/53) of those diagnosed before and
after 2012 respectively were ART-naïve. The overall rate of early diagnosis pre-2013 was 0.57
cases per 100 p-y (95% CI 0.44–0.73) and 28 per 100 p-y (95% CI 21.15–37.03) in 2013
(p<0.0001). Early diagnosis was higher among ART-naive compared to those on ART (4.07
per 100 p-y (95% CI 3.10–5.36) vs 0.61 per 100 p-y (95% CI 0.47–0.78) respectively). Indepen-
dent predictors of early diagnosis did not differ from those of the entire cohort.
Discussion
In this large study including 5123 HIV infected patients enrolled in a rural African HIV pro-
spective cohort between 2005 and 2013, the previously stable TB incidence rate dramatically
Table 2. Incidence rates of Tuberculosis ascertainment among HIV patients enrolled in KIULARCO per selected characteristics.
Characteristics Overall Incidence
rates (per 100
person years)
95% CI P value Early incidence
rates (per 100
person years)
95% CI P value Incidence rate one
month after registration
(per 100 personyears)
95%CI P value
Sex
Female 3.43 3.03–3.87 0.06 0.88 0.69–1.12 0.08 2.55 2.21–2.93 0.26
Male 3.98 3.38–4.67 1.23 0.92–1.65 2.75 2.13–3.12
Age group
Adults 18 3.50 3.15–3.89 0.21 0.95 0.78–1.16 0.2 2.55 2.26–2.89 0.48
Children<18 4.40 3.31–5.83 1.37 0.82–2.28 3.02 2.15–4.25
WHO clinicalstage
1 and 2 2.31 1.91–2.81 <0.0001 0.46 0.30–0.71 <0.0001 1.85 1.49–2.29 <0.0001
3 and 4 8.30 7.27–9.46 2.80 2.23–3.51 5.51 4.68–6.47
ART treatment
No 7.67 6.28–9.37 <0.0001 4.07 3.10–5.36 <0.0001 3.63 2.71–4.86 0.1
Yes 3.09 2.77–3.46 0.61 0.47–0.78 2.48 2.19–2.81
Smoking
No 3.36 3.00–3.77 0.92 1.04 0.84–1.28 0.06 2.32 2.02–2.66 0.18
Yes 3.66 2.73–4.91 0.57 0.27–1.19 3.10 2.26–4.27
History of any chronic
disease
No 3.32 2.97–3.72 0.32 0.97 0.78–1.19 0.39 2.36 2.06–2.70 0.54
Yes 3.63 2.63–5.01 1.07 0.59–1.94 2.56 1.74–3.76
Periodofregistration
(years)
Before 2013 2.96 2.66–3.30 <0.0001 0.57 0.44–0.73 <0.0001 2.39 1.93–2.46 <0.0001
2013 43.98 35.18–
54.99
27.99 21.15–
37.03
16.36 11.29–
23.69
Chronic diseases include arterial hypertension, diabetes mellitus and cancer. TB: tuberculosis; Conﬁdence interval; WHO: World Health Organization;
ART: Antiretroviral treatment
doi:10.1371/journal.pone.0123275.t002
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increased after the introduction of a bundle of services consisting of the integration of HIV and
TB services within one single facility, use of GeneXpert, and implementation of an electronic
data collection system. In addition, the bundle of services had an impact on early detection of
TB among ART naïve patients. Moreover the strongest predictor of TB identified was registra-
tion in the clinic after the introduction of the bundle of services. To our knowledge this is the
first report to show the impact of such a bundle of services on tuberculosis ascertainment in Af-
rica. Previous studies on trends of TB case notification in Africa have indicated a decrease in
trend among HIV patients following scaling up of ART [5,6]. We implemented system changes
which emphasize intensification of screening for TB among HIV patients and optimized data
recording which resulted into identifying more TB incident cases. Thus, our findings suggest a
potential under-diagnosis and/or under-reporting of TB among HIV infected individuals in
similar rural African settings.
Our findings concur with previous studies from sub-Saharan Africa showing an increase of
TB diagnosis when TB and HIV programs are integrated and TB screening intensified[9–11].
Integration of both programs in one single health facility provides an opportunity for early
Table 3. Cox regression analysis of risk factors for tuberculosis ascertainment by period.
2005–2013 Pre-2013 Post 2013
Characteristics Unadjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95%CI)
Unadjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95%CI)
Unadjusted hazard
ratio (95% CI)
Adjusted hazard
ratio (95%CI)
Gender
Female 1 1 1 1 1 1
Male 1.20 (0.98–1.48) 1.12 (1.85–1.47) 1.11 (0.89–1.40) 0.93 (0.67–1.31) 1.97 (1.25–3.09) 1.72 (1.02–2.87)
Age group (years)
18 1 1 1 1 1 1
<18 1.31 (1.07–1.61) 1.02 (0.68–1.50) 1.03 (0.72–1.46) 1.03 (0.65–1.65) 2.67 (1.50–4.80) 1.24 (0.57–2.68)
Marital status
Married 1 1 1 1 1
Not Married 1.31 (1.07–1.61) 1.27(0.97–1.66) 1.21 (0.96–1.52) 1.15 (0.84–1.57) 2.41 (1.48–3.90) 1.35 (0.77–2.34)
WHO stage
I/II 1 1 1 1 1 1
III/IV 3.22 (2.54–4.06) 2.48 (1.88–3.26) 2.82 (2.17–3.66) 1.94 (1.43–2.65) 4.50 (2.58–7.83) 3.97 (2.14–7.32)
ART
Yes 1 1 1 1 1 1
No 2.12 (1.69–2.67) 2.97 (2.25–3.94) 1.12 (0.82–1.53) 1.42 (0.94–2.13) 9.35 (5.80–15.1) 11.1 (6.5–1874)
Smoking
No 1 1 1 1 1 1
Yes 1.01 (0.74–1.39) 1.21 (0.81–1.82) 1.27 (0.91–1.77) 1.28 (0.83–1.96) 1.20 (0.29–4.90) 1.90 (0.43–8.34)
Chronic disease¤
No 1 1 1 1 1 1
Yes 6.30 (4.83–8.21) 1.36 (0.92–1.99) 1.09 (0.76–1.56) 1.50 (1.01–2.21) 0.91 (0.13–6.52) 1.50 (0.19–11.27)
Functional status
Working 1 1 1 1 1
Ambulatory or
bedridden
6.20 (4.90–7.83) 3.89 (2.87–5.28) 6.59 (5.07–8.57) 4.80 (3.36–6.83) 4.44 (2.64–7.46)
Registration (year)
Before 2013 1 1
2013 6.30 (4.83–8.21) 6.07 (4.39–8.38)
doi:10.1371/journal.pone.0123275.t003
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diagnosis of HIV among TB patients as well as early diagnosis of TB among HIV patients[9].
Different models have been implemented to integrate TB and HIV care, ranging from models
including referrals between the two clinics to more comprehensive models offering care under
one facility[12]. The latter, though demanding in organizational and administrative structure,
has proved to be more effective [12]. However, some challenges exist including training and re-
tention of staff, and infection control[12].
GeneXpert has been shown to have a high sensitivity and specificity for TB diagnosis [7,13].
Previous studies in high burden countries have indicated an increase in TB case reporting
when GeneXpert was used compared to sputum microscopy[7,14–16]. Vassall A (2011) et al
observed an overall increase in TB detection in India, South Africa and Uganda from 72%-85%
to 95%-99% [14]. Results from a decision model study from South Africa on impact of national
scaling up suggested a potential 30%-37% increase in the number of TB cases diagnosed per
year[17]. Another study in the same setting indicated an increase of 45% in HIV associated TB
detection when GeneXpert was used compared to smear microscopy[15]. However, the value
of GeneXpert in high TB burden settings where empirical treatment is common has been re-
cently questioned, suggesting that in these settings wide GeneXpert use may displace empirical
treatment instead of improving outcomes and disease burden [18]. Empirical treatment at the
CDCI was initiated after negative microbiological tests, a course of antibiotics without effect,
and a radiography suggestive of TB. We observed an increase of almost fifteen-fold in the rate
of TB ascertainment after introduction of the bundle of services including GeneXpert use.
However, our findings of an increased TB ascertainment do not seem to be fully explained by
the use of GeneXpert, since it only accounted for 12% of additional TB cases detected in 2013.
Previous studies have reported that the use of electronic system in medical records help im-
prove health care quality in general and for HIV/AIDS patients [19–22]. We replaced the previ-
ous paper-based system with the electronic system, which prompts clinicians to inquire and
report all required information. Specifically, clinicians are compelled to collect information on
the screening of symptoms and signs of TB in every visit and report the cases using ICD-10
codes. TB screening among all HIV-infected individuals attending the clinic is currently per-
formed at all visits and all TB patients are in turn routinely screened for HIV. This suggests
that the observed increase in incidence rates of TB ascertainment was partly due to changes in
recording systems as well as improved clinical information collection tools. Indeed, 84% of all
TB/HIV cases recorded at the National Tuberculosis and Leprosy Programme (NTLP) from
our hospital were captured in the KIULARCO database 2013a 68% increase from the period
prior to 2013.
There are limited data on the incidence of TB notification among HIV patients in Tanzania.
The latest estimates of prevalence of TB by the WHO and the Tanzanian Ministry of Health
are 177 per 100,000 persons and 295 per 100,000 persons respectively among the general popu-
lation [26,27]. In 2013, we obtained an overall estimated incidence notification rate of 44 cases
per 100 p-y. Due to the lack of comparative studies in similar populations, our findings provide
relevant information to assess the incidence rates of TB among HIV patients in Tanzania.
However, this incidence rate is high compared to previous estimations from South Africa (9.2
cases per 100 person-years)[28]. Importantly, despite acknowledging a potential overestima-
tion, our findings reflect the incidence of tuberculosis in a “real-life” rural African setting, with
a high proportion of clinical diagnosis and empiric treatment. The incidence of TB diagnosis in
children was estimated to be 4.4 per 100 p-y slightly, similar to previous results from Dar es Sa-
laam (5.2 per 100 p-y)[29]. As expected, we observed a lower rate of TB notification among
those who were on ART compared to ART-naive patients, concurring with a number of studies
showing reduction in the risk of TB among HIV patients on ART[30–35]. Remarkably, we also
observed an increase in early TB notification after implementing system changes. Eighty one
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percent of patients diagnosed early in 2013 were ART naïve at the time of TB diagnosis, com-
pared to 75% pre-2013. Increasing TB notification among ART-naïve individuals has impor-
tant clinical implications, reducing the incidence of immune reconstitution inflammatory
syndrome (IRIS), and increasing survival[36].
Four baseline factors were identified as independent predictors of TB, including WHO clini-
cal stage 3 or 4, ART naivety, poor functional status, and registration in 2013. There were not
remarkable differences in predictors of TB ascertainment between pre- and post 2013. Our
findings are similar to those by Illiyasu Z et al. in which marital status, WHO stage and CD4
+ count predicted TB occurrence [37]. We did not include CD4+ count in the multivariable
model due to significant missing values, which would have resulted into an unstable model.
However, we presented the univariable estimates that suggested that CD4+ count was an im-
portant predictor of TB notification in our population. An attempted sensitivity analysis by in-
cluding missing values on CD4+ count through imputation of the mean did not modify the
results and the rate of TB notification was still higher among those with CD4+ count
350cells/μl. Remarkably, registration in 2013 was the strongest predictor of TB notification
even after excluding early TB notification in sensitivity analysis, suggesting a critical role of the
bundle of services introduced in December 2012.
This study has certain limitations. First, due to the combined introduction of the three inter-
ventions, the improvement in TB ascertainment could not be attributed to any particular inter-
vention but to the bundle of services. However, supporting other observations, GeneXpert does
not seem to have played a prominent role in increasing TB ascertainment. Second, a longer fol-
low-up will be needed to measure the long-term impact of this strategy. Despite the extent of
missing values on baseline WHO clinical stage and CD4+ count being more than 10%, it is un-
likely that our study population was biased due to missing data since the characteristics of the
study population and that of the whole cohort did not differ. Third, we acknowledge that the
influence of other factors such as changes in clinical administration and motivation of clini-
cians may have contributed. However, these factors are not easily measured. Fourth, our find-
ings indicate an increase in diagnosis of TB within the KIULARCO cohort, but it has been
difficult to estimate accurately whether the impact of this bundle of services also resulted in an
increased notification to the National Tuberculosis and Leprosy Program. Finally, we recognize
the potential for information bias and record error, since tuberculosis cases for this study were
entirely based on records in the database.
There are several clinical and public health implications of our findings, particularly in light
of the striking disparity in TB ascertainment and reporting before and after the implementation
of the bundle of services in our clinic. First, our results support the need for a switch from verti-
cal models to comprehensive care models in rural sub-Saharan Africa. The integration of TB
and HIV services within one single facility is a first step in this direction. This integration al-
lowed for the systematic application of diagnostic algorithms including clinical information,
chest radiography, and a true point-of-care use of GeneXpert, providing results in less than two
hours, and decreasing the waiting time and travel expenses for our patients. GeneXpert is being
progressively rolled out in sub-Saharan Africa, but as important as its roll out is the adaptation
of the health facilities to this new technology and its full integration within the existing routine
diagnostic algorithms to maximize its potential benefits. Second, our findings stress the several
advantages of the replacement of clinic logs with electronic medical records, which we believe
should be a public health priority in these settings to optimize clinical efficiency and epidemio-
logical surveillance. Finally our results suggest the possibility of an under-ascertainment of
TB-HIV in similar settings in Tanzania and other sub-Saharan African countries. TB is the first
cause of death among HIV-infected patients in Africa, and can be fatal if non-diagnosed and
treated timely. Moreover, ART initiation in non-diagnosed active TB cases may result in the
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development of unmasking TB-IRIS, posing a tremendous clinical challenge to clinicians in
these settings and carrying significant morbidity and mortality if not properly managed.
In summary, we believe that integrating tuberculosis and HIV services together with a com-
prehensive electronic data collection and use of appropriate diagnostic tools are pivotal in as-
sessing the burden of tuberculosis among HIV-positive patients and may contribute to
decrease the unacceptably high HIV-TB-associated mortality in Africa. Further studies to as-
sess the potential effects of similar strategies on this and other clinical outcomes are warranted.
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